Gupta Deepak, Zachariah Anita, Roppelt Heidi, Patel Aarat M, Gruber Barry L
Division of Rheumatology, Allergy and Immunology, Department of Medicine, State University of New York at Stony Brook, Stony Brook, New York 11794-8161, USA.
J Clin Rheumatol. 2008 Oct;14(5):267-72. doi: 10.1097/RHU.0b013e31817a7e30.
Use of cyclophosphamide in systemic lupus erythematosus (SLE) is associated with Pneumocystis jirovecii pneumonia (PJP) that has substantial morbidity and mortality. However, the frequency of PJP in these patients is unknown and there are no guidelines for prophylactic antibiotics.
The objectives of this study are to evaluate the frequency of PJP and the need for prophylactic antibiotics in these patients.
We estimated incidence of PJP and use of prophylactic trimethoprim-sulfamethoxazole in these patients by a literature search and an e-mail survey of US rheumatologists.
We identified 18 manuscripts dealing with infections in SLE patients treated with cyclophosphamide. In these manuscripts, 121 cases of PJP were identified in 76,156 SLE patients with a frequency of 15.88 per 10,000 patients.Of 264 rheumatologists surveyed, 133 (50.37%) were using prophylactic antibiotics in these patients. One hundred thirty-one (49.63%) respondents did not use prophylactic antibiotics. 5,174 SLE patients received cyclophosphamide in last 5 years with 19.6 +/- 30.6 (mean +/- SD) patients per rheumatologist. 32 cases of PJP were reported. The total cumulative experience of 264 rheumatologists was 4742 years [(17.96 +/- 10.35) (mean +/- SD)] with a PJP rate of 67.48 per 10,000 years of practice.
The frequency of PJP in SLE patients on cyclophosphamide remains low (0.1588%). Therefore, routine use of trimethoprim-sulfamethoxazole for PJP prophylaxis in SLE patients on cyclophosphamide does not appear to be substantiated by this study, except in those with elevated risk, ie, with severe leucopenia, lymphopenia, high dose corticosteroids, hypocomplementemia, active renal disease, and higher mean SLEDAI score. There is a need for consensus guidelines addressing prophylactic antibiotics in these patients.
在系统性红斑狼疮(SLE)中使用环磷酰胺与耶氏肺孢子菌肺炎(PJP)相关,后者具有较高的发病率和死亡率。然而,这些患者中PJP的发生率尚不清楚,且尚无预防性使用抗生素的指南。
本研究的目的是评估这些患者中PJP的发生率以及预防性使用抗生素的必要性。
我们通过文献检索和对美国风湿病学家的电子邮件调查,估计了这些患者中PJP的发生率以及预防性使用甲氧苄啶-磺胺甲恶唑的情况。
我们确定了18篇关于接受环磷酰胺治疗的SLE患者感染情况的手稿。在这些手稿中,在76156例SLE患者中发现了121例PJP,发生率为每10000例患者15.88例。在接受调查的264名风湿病学家中,133名(50.37%)在这些患者中使用预防性抗生素。131名(49.63%)受访者未使用预防性抗生素。在过去5年中,5174例SLE患者接受了环磷酰胺治疗,每位风湿病学家平均治疗19.6±30.6(均值±标准差)例患者。报告了32例PJP。264名风湿病学家的总累积经验为4742年[(17.96±10.35)(均值±标准差)],PJP发生率为每10000年实践67.48例。
接受环磷酰胺治疗的SLE患者中PJP的发生率仍然较低(0.1588%)。因此,除了那些风险较高的患者,即严重白细胞减少、淋巴细胞减少、高剂量糖皮质激素、低补体血症、活动性肾脏疾病和较高平均SLEDAI评分的患者外,本研究似乎并未证实对接受环磷酰胺治疗的SLE患者常规使用甲氧苄啶-磺胺甲恶唑预防PJP的合理性。需要针对这些患者预防性使用抗生素制定共识指南。